Amgen revenue decreased from $23.7 billion in 2018 to $23.4 billion in 2019, a (1.6%) decrease.
Annual Revenue ($)
Amgen revenue was $23.36 b in FY, 2019 which is a (1.6%) year over year decrease from the previous period.
Quarterly Revenue ($)
Annual Growth Rate (%)
Revenue Breakdown
Business Segment
Geographic Segment
Amgen revenue breakdown by business segment: 22.4% from Enbrel, 13.8% from Neulasta, 11.4% from Prolia, 8.3% from XGEVA, 7.4% from Aranesp, 21.2% from Other products and 15.5% from Other
Amgen revenue breakdown by geographic segment: 25.5% from Rest of World and 74.5% from United States
| FY, 2019 | FY, 2018 | FY, 2017 | |
|---|---|---|---|
| Enbrel | $5.23 b | $5.01 b | $5.36 b |
| Neulasta | $3.22 b | $4.48 b | $4.72 b |
| Prolia | $2.67 b | $2.29 b | $1.31 b |
| XGEVA | $1.94 b | $1.79 b | $1.41 b |
| Aranesp | $1.73 b | $1.88 b | $951 m |
| KYPROLIS | $1.04 b | $512 m | |
| EPOGEN | $867 m | $1.01 b | $1.86 b |
| Sensipar/Mimpara | $551 m | $1.77 b | $1.42 b |
| Other products | $4.96 b | $4.31 b | $2.41 b |
| Other revenues | $1.16 b | $1.21 b | $718 m |
| FY, 2019 | FY, 2018 | FY, 2017 | FY, 2016 | |
|---|---|---|---|---|
| Rest of World | $5.67 b | $5.1 b | $4.66 b | $4.57 b |
| United States | $16.53 b | $17.43 b | $17.13 b | $17.33 b |
Need Data?
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.